X4 Pharmaceuticals, Inc. diskutieren
X4 Pharmaceuticals, Inc.
WKN: A2PFVY / Symbol: XFOR / Name: X4 Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,17 €
-2,31 %
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at B. Riley.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target raised by analysts at HC Wainwright from $3.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at HC Wainwright from $5.00 to $1.50. They now have a "buy" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target raised by analysts at HC Wainwright from $1.50 to $7.00. They now have a "buy" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) had its price target lowered by analysts at Stifel Nicolaus from $30.00 to $9.00. They now have a "buy" rating on the stock.
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for XFOR provided by MarketBeat
Neueste Beiträge
Roth_Capital in Discuss Vicor Corp.